Company History
EuBiologics Co., Ltd. is growing by leaps and bounds and contributing to global public health through innovative products and technology.
2020
- 10Established a joint venture company, EUPOP Life Sciences, with POP Biotechnologies, Inc. of USA
2019
- 12Received 20 Million Dollar Export Tower Award
- 04Completed construction of Plant 2 (V Plant) in Chuncheon, Korea
2018
- 12Received 10 Million Dollar Export Tower Award
- 03Started construction of Plant 2 (V Plant) in Chuncheon, Korea
2017
- 12Entered into the EcML Technology Transfer Agreement with KIST
- 08Received WHO Prequalification certificate for OCV (Euvichol-Plus)
- 01Listed on KOSDAQ
2016
- 10Started exporting OCV (Euvichol¢ç) (including one million doses to Haiti, etc.)
- 06Entered into the Long-Term Agreement with UNICEF for OCV (Euvichol¢ç) supply
2015
- 12Received WHO PQ certification for OCV (Euvichol¢ç)
- 01Received export license for OCV (Euvichol¢ç) from KMFDS
2014
- 09Expanded production facilities for Active Pharmaceutical Ingredient for Euvichol¢ç (w.v.600L)
- 08Completed Phase 3 Clinical Trial for OCV (Euvichol¢ç) in Philippines
- 08Received investment from Global Health Investment Fund (GHIF) of the Bill and Melinda Gates Foundation
2013
- 12Received IND approval for Phase 3 Clinical Trial of OCV (Euvichol¢ç) in Philippines
2012
- 07IND approved for Phase 1 Clinical Trial of OCV (Euvichol¢ç) in Korea
- 06Conducted Government Assignment for next generation typhoid vaccine (Small and Medium Business Administration)
- 03Merged with EuBiopharm Co., Ltd.
- 02Received the Venture Company Certificate
2010
- 12Performed the Technology Transfer and Feasibility study
- 09Entered into the Technology Transfer Agreement for oral cholera vaccine (OCV) with International Vaccine Institute (IVI)
- 03EuBiologics Co., Ltd. founded